Nausea Clinical Trial - Reletex for Nausea in GERD Patients

Status Terminated

Clinical Trial Summary

Gastroesophageal reflux disease (GERD) is a highly prevalent condition that is frequently encountered in the health care setting. It affects roughly 40% of Americans monthly and 10% weekly. Of those with GERD, there exists a cohort that experience nausea with or without vomiting that is unresponsive to PPI's and anti-emetics. For these patients, treatment options are limited and these symptoms may substantially alter their quality of life. New and novel therapies emerging include neuromodulation devices that may affect the central pathways leading to these symptoms. Of these, the Reletex band has been tested and proven efficacious in the treatment of nausea and vomiting associated with pregnancy, chemotherapy, and surgery, in addition to standard anti-nausea medications. The investigators propose that through a similar mechanism, this device as an adjunct to PPI's and anti-emetics will reduce GERD-associated the nausea with or without vomiting, and by so doing, improve the quality of lives in this patient population.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Nausea

Clinical Trial Details

NCT number	NCT01582100
Study type	Interventional
Source	Northwestern University
Contact
Status	Terminated
Phase	N/A
Start date	March 2012
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01649258` - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy	Phase 1
Completed	`NCT02939287` - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan	Phase 3
Not yet recruiting	`NCT06464926` - Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)	N/A
Not yet recruiting	`NCT06055192` - Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Recruiting	`NCT04091789` - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea	Phase 2
Completed	`NCT02462811` - A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)	Phase 3
Completed	`NCT01007500` - Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery	Phase 4
Recruiting	`NCT00528554` - Laser Acupuncture Against Nausea in Children	N/A
Completed	`NCT00537875` - Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens	N/A
Completed	`NCT00394966` - A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)	Phase 2
Completed	`NCT00947128` - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions	Phase 1
Completed	`NCT00946387` - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions	Phase 1
Recruiting	`NCT05433636` - Mindful Waiting Room	N/A
Not yet recruiting	`NCT04827108` - Psychometric Properties of the Chinese Version of PeNAT
Not yet recruiting	`NCT04853303` - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK	N/A
Terminated	`NCT04247100` - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders	N/A
Recruiting	`NCT04181346` - Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting	Phase 2
Recruiting	`NCT03679182` - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care	Phase 2
Completed	`NCT02618343` - EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron	N/A
Terminated	`NCT01405924` - Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)	Phase 2